• External link opens in new tab or windowinfo@cvipharma.com
CVI Pharma
Menu
  • Link Icon Link Icon Link Icon Home
    • External link opens in new tab or window Link Icon Link Icon Link Icon About Us
      • Link Icon Link Icon Link Icon Our Pipeline
        • Link Icon Link Icon Link Icon Investors and news
          • External link opens in new tab or window Link Icon Link Icon Link Icon Contact Us

            CardioVascularInnovation

            New Biopharmaceutical Products

            At CVI Pharmaceuticals Limited, we never cease in discovering


            Leading Healthcare Investors

            CVI Pharmaceuticals Limited works with various healthcare investors


            Contact Our Biopharmaceutical Company

            Make CVI Pharmaceuticals Limited your trusted biopharmaceutical firm.


            Leader in Cardiovascular Innovation

            Developing Treatments for Hypercholesterolemia and NAFLD/NASH

            For more than 10 years, CVI has been addressing the unique and unprecedented unmet needs in cardiometabolic diseases through innovative therapeutics. Our clinical-stage biopharma company is focused on developing new, first-in-class, small-molecule oral therapies that can help treat hypercholesterolemia, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), obesity, and rare metabolic diseases.

            Inquire About Our

            Cholesterol-Lowering Medications

            Make CVI Pharmaceuticals your trusted biopharmaceutical company. Support our mission in discovering and developing new cholesterol-lowering medications that will specifically help cure hypercholestertolemia and ameliorate fatty liver diseases.

            Read MoreRead More


            Ground-Breaking Products Development

            With partnerships with various healthcare investors, we have spearheaded in-depth studies in cholesterol-lowering, oral drugs that can aid in the treatment of cardiometabolic diseases. Our company’s lead product candidate is CVI-LM001, which is currently at phase 2 proof-of-concept clinical development stage for the treatment of hypercholesterolemia. CVI-LM001 is a novel, first-in-class, safe, and oral once-daily PCSK9 modulator with a distinct mechanism of actions.

            Learn More About Our Biopharma Company

            Thank you for taking the time to view our website. Should you have any questions about our company or the treatments we develop for various cardiometabolic diseases, get in touch with us. Our experts are here to provide you with more details about our work. Please contact us via phone, email, or this website. We will get back to you as soon as we can.

            CVI Pharmaceuticals Limited


            External link opens in new tab or window86-21-50207196

            info@cvipharma.com

            Contact Us

            Invalid Form properties detected





            Location

            898 Ha Lei Road, Building 1, Suite 304, Zhang Jiang High Tech Park, Pudong New District, Shanghai, China 201203

            counter free
            close lightbox